IL22 and myeloid sarcoma: These beneficial effects were associated to an increased number of CD4+CD25+FOXP3+ Tregs within the spinal cords, a reduced release of pro-inflammatory cytokines (including IL-6, IL-12p70, IL-17AF, and IL-22), suggesting exosome-MSCs as a promising therapeutic tool for MS patients [101].